Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have ...
Heart failure with reduced ejection fraction (HFrEF) describes a type of heart failure in which the heart loses its ability to contract typically. Because of this, the heart cannot pump with enough ...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ...
Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...
Medical experts discuss benefits of titrating therapies for management of ejection fraction pathologies. Ryan Haumschild, PharmD, MS, MBA: Dr Anderson, I’d like to start with you. We’ve talked about ...
CLEVELAND -- Lower doses of copper chelator trientine hydrochloride (Syprine) appeared safe and potentially promising for heart failure with low ejection fraction in a phase IIa trial, despite a ...
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart does not fill with blood properly. In HFpEF, the heart can pump normally, but the heart is stiff and cannot ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results